Topics:

Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

Pathologic and molecular features of gastrointestinal stromal tumors (GIST) were generally not correlated with outcome in a study involving adjuvant imatinib therapy following resection of the primary tumor.

This slide show features a CT image, and pathology images of gastrointestinal stromal tumors (GISTs) arising in the stomach using H&E, CD34, and c-Kit staining.

A majority of patients on imatinib for treatment of GIST or CML had low or absent levels of osteocalcin, a bone marker secreted by osteoblasts, and about 50% of patients had a decrease in bone mineral density, signaling that long-term treatment may affect bone health in these patients.

We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling pathways in the heterogeneous tumors of mesenchymal origin—spurred by the identification of c-Kit–activating mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the tyrosine kinase inhibitor imatinib (Gleevec).

Treatment of gastrointestinal stromal tumor (GIST) with regorafenib after prior treatment failure with both imatinib and sunitinib resulted in a PFS survival benefit for patients across all prespecified subgroups.

Though the calcium-dependent chloride channel DOG1 is strongly expressed in gastrointestinal stromal tumors (GIST), a new laboratory study suggests that methods targeting it for therapies in treating these cancers are still a ways off.

The FDA has granted imatinib full approval as an adjuvant treatment following surgical removal of CD117-positive gastrointestinal stromal tumors in adult patients. This comes after results from a phase III trial showed that patients taking imatinib for 36 months had a 5-year overall survival of 92%, compared to 82% for those patients who took the drug for the standard 12 months of treatment.

Pages

Subscribe to Gastrointestinal Stromal Tumor on [sitename]

CME Center

Earn CME Credits for reading Psychiatric Times articles. Click here to go to our free online CME activities.

By clicking Accept, you agree to become a member of the UBM Medica Community.